Beta-blocker therapy has been shown to benefit patients who have coronary artery disease and present with acute myocardial infarction(AMI) and/or congestive heart failure(HF). However, whether β-blocker therapy provi...Beta-blocker therapy has been shown to benefit patients who have coronary artery disease and present with acute myocardial infarction(AMI) and/or congestive heart failure(HF). However, whether β-blocker therapy provides a similar benefit in patients who have coronary artery disease but not AMI or HF is unknown. A population of 4,304 patients who did not have HF but did have angiographically confirmed coronary artery disease(≥1 stenosis of ≥70%) without AMI at hospital presentation was evaluated. Baseline demographics, cardiac risk factors, clinical presentation, therapeutic procedures, and discharge medications were recorded. Patients were followed for a mean of 3.0±1.9 years(range 1 month to 6.9 years) for outcomes of all-cause death or AMI. Patients’average age was 65±11 years and 77%were men. Overall, 10%died and 5%had a nonfatal AMI. Discharge β-blocker prescription was associated with an increased event-free AMI survival rate for all-cause death(no βblocker 88.3%, βblocker 94.5%, p< 0.001) and death/AMI(no βblocker 83.4%, βblocker 89.2%, p< 0.001) but not non-fatal AMI(no βblocker 93.6%,βblocker 94.1%, p=0.60). After adjustment for 16 covariates, including statin prescription, angiotensin-converting enzyme inhibitor prescription, and type of baseline therapy, the effect of βblockers on the combination end point of death/AMI was eliminated. However, the effect of βblockers on death remained(hazard ratio 0.66, 95%confidence interval 0.47 to 0.93, p=0.02). Thus, βblockers are clearly indicated for most patients who have HF or AMI, and our results suggest that patients who have coronary artery disease without these conditions have approximately the same protective benefit against death. No effect was observed on longitudinal incidence of AMI or the combination of death/nonfatal MI.展开更多
文摘Beta-blocker therapy has been shown to benefit patients who have coronary artery disease and present with acute myocardial infarction(AMI) and/or congestive heart failure(HF). However, whether β-blocker therapy provides a similar benefit in patients who have coronary artery disease but not AMI or HF is unknown. A population of 4,304 patients who did not have HF but did have angiographically confirmed coronary artery disease(≥1 stenosis of ≥70%) without AMI at hospital presentation was evaluated. Baseline demographics, cardiac risk factors, clinical presentation, therapeutic procedures, and discharge medications were recorded. Patients were followed for a mean of 3.0±1.9 years(range 1 month to 6.9 years) for outcomes of all-cause death or AMI. Patients’average age was 65±11 years and 77%were men. Overall, 10%died and 5%had a nonfatal AMI. Discharge β-blocker prescription was associated with an increased event-free AMI survival rate for all-cause death(no βblocker 88.3%, βblocker 94.5%, p< 0.001) and death/AMI(no βblocker 83.4%, βblocker 89.2%, p< 0.001) but not non-fatal AMI(no βblocker 93.6%,βblocker 94.1%, p=0.60). After adjustment for 16 covariates, including statin prescription, angiotensin-converting enzyme inhibitor prescription, and type of baseline therapy, the effect of βblockers on the combination end point of death/AMI was eliminated. However, the effect of βblockers on death remained(hazard ratio 0.66, 95%confidence interval 0.47 to 0.93, p=0.02). Thus, βblockers are clearly indicated for most patients who have HF or AMI, and our results suggest that patients who have coronary artery disease without these conditions have approximately the same protective benefit against death. No effect was observed on longitudinal incidence of AMI or the combination of death/nonfatal MI.
